1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > JAK and PI3K Signaling Pathway Markets

JAK and PI3K Signaling Pathway Markets

  • April 2014
  • -
  • BCC Research
  • -
  • 143 pages

REPORT HIGHLIGHTS

The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion in 2018 with a compound annual growth rate (CAGR) of 36.8% over the five-year period from 2013 to 2018.

This report provides:

An overview of the global market for signal transduction therapies and inhibitors
Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018
Information on approved products such as Ruxolitnib, as well as others in devlopment
Discussion of the regulatory environment which is impacting development
Relevant patent analysis
Profiles of leading companies in the industry

STUDY OBJECTIVES

The intent of the report carried out by BCC Research was to assess, explore and envisage the market potential of signal transduction therapies and to review the advancement of the several candidates in their clinical developments for therapies concerning the aberrant signals through janus kinase (JAK) and phosphoinositide 3-kinases (PI3K) pathways. The emerging market analysis for the therapies associated with JAK and PI3K deviant cellular signals is brought together from the approved product performance, the notable clinical developments, the judicious collaborations for advancement of successful research, commercialization plans, huge market opportunities, etc.

The report establishes a balanced projection on the budding market of JAK and PI3K based signal transduction therapies with just two products ruxolitinib (Jakafi) and tofacitinib (Xaljanz). Ruxolitinib was approved in November 2011 for myelofibrosis while tofacitinib was approved in November 2012 for rheumatoid arthritis, respectively. The report also projects the future market for the said therapies, candidate details and their clinical development status, biomarker research, market leaders and market shares, profile of leading companies, collaboration and commercialization strategies, technology platforms and new developments, regulatory aspects, patent details, opportunities and challenges, and drivers and factors determining the signal transduction therapies market for JAK and PI3K.

The sales data for ruxolitinib and tofacitinib is secured from the germane sources that comprise the annual reports of the manufacturing companies and other data sources. Market analysis is conducted for the periods from 2011 until 2013. The report also presents the revenue forecast for the year 2018 with a drilled down analysis on the region wise data for North America (U.S. and Canada), Europe and emerging markets for the examined period.

REASONS FOR DOING THIS STUDY

Significant developments have come about in both the understanding of the complexity of signal transduction pathways such as JAK and PI3K over the past couple of years. At the same time, much progress occurred in the isolation of target specific therapies/inhibitors for the abnormal signals in those pathways. The therapies for JAK and PI3K cellular signal pathways predominantly focus on the cancer lines and inflammatory diseases after the approval of ruxolitinib (for myelofibrosis) and tofacitinib (for rheumatoid arthritis). Although other diseases categories like asthma, skin, respiratory and eye disorders are also being explored largely. The report portrays the prospective therapeutic application of the JAK and PI3K inhibitors/therapies/biomarkers from the perspective of their market opportunity, disease targets, clinical development progress, etc.

The growing market of therapies related to JAK and PI3K signal pathways have tremendous opportunity to grow since these therapies have the potential to target diseases like cancer and inflammatory diseases with no appropriate medications so far. The current therapies are capable of reducing the disease burden but cannot cure. Furthermore, there is a growing patient base worldwide for cancers and inflammatory diseases.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM

The report emphasizes on the prospective remedial relevance of the signal transduction therapies for JAK and PI3K signaling pathways as well as the market demand of those therapies. The major developments in this category of medical science would be useful for the product developers/manufacturers/producers, multinationals, scientists, researchers, research universities, government and non-government organizations, and others.

SCOPE OF THE STUDY

BCC Research conducted the market evaluation, the global and regional breakdown of sales data, present and prospective application of the therapies, market forecasting, success and challenges, patent details, regulatory facet, clinical developments, market leaders and market share of the maturing market for JAK and PI3K inhibitors/therapies/biomarkers.
The sales data for the global and regional markets is validated for the present and projected values through scientific and statistical analysis. The information regarding the approved products and candidates as well as the technologies/platforms are provided based on their present/prospective application and viability.

METHODOLOGY

BCC Research composed all relevant information for the report on signal thransduction therapies/inhibitors/biomarkers for JAK and PI3K signaling pathways through primary as well as secondary research methodologies. BCC Research interviewed industry practice leaders that included developers/producers of JAK and PI3K therapies, domain experts, scientists and other veterans from the industry. Furthermore, BCC Research conducted searches through several information sources. Market predictions depict the probable unit prices, usage of JAK and PI3K inhibitors/therapies/biomarkers, present-day economy and conceivable application of JAK and PI3K inhibitors/therapies/biomarkers.

INFORMATION SOURCES

BCC Research explored appropriate organizations and companies to accrue relevant data associated with JAK and PI3K inhibitors/therapies/biomarkers. The organizations were key producers and research organizations/universities of JAK and/or PI3K therapies. BCC Research also met with representatives of the companies and research groups to achieve deeper insights on the future perspectives of signal transduction therapies for JAK and PI3K signaling pathways.
BCC Research reviewed scientific journals, booklets, research papers and articles, company white papers, pharmaceutical and other relevant newsletters, science digests, online medical libraries, medical and pharmaceutical blogs, news feeds, medical papers and journals, newsletters, company literature and financial reports, product literature, periodicals, abstracts, regulatory aspects, technical articles, bulletins, patent files, pharmaceutical biopharmaceutical and medicine databases, etc.

Table Of Contents

JAK and PI3K Signaling Pathway Markets
Chapter- 1: INTRODUCTION4

STUDY OBJECTIVES
REASONS FOR DOING THIS STUDY
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ABOUT THE AUTHOR
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER

Chapter- 2: EXECUTIVE SUMMARY

Table Summary : GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018
Figure Summary : GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018)

Chapter- 3: OVERVIEW

JANUS KINASE (JAK) AND PHOSPHOINOSITIDE 3-KINASES (PI3K)
SIGNAL TRANSDUCTION THERAPIES/INHIBITORS FOR JAK AND PI3K
CLASSIFICATION
SIGNAL TRANSDUCTION BIOMARKERS FOR JAK AND PI3K
PROSPECTIVE DISEASE TARGETS FOR JAK AND PI3K THERAPIES

Chapter- 4: REGULATORY ASPECTS

RUXOLITINIB (INC424)
TOFACITINIB (CP-690,550)
REGULATORY DEVELOPMENTS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS

Chapter- 5: NEW DEVELOPMENTS

NEW DEVELOPMENTS
COLLABORATIVE TRIALS AND FUTURE ACTIVITIES

Chapter- 6: MARKET ANALYSIS-SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)

MARKET BY THE TYPE
MARKET BY REGION
PROSPECTIVE FUTURE MARKET FOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)
INDUSTRY STRUCTURE
MARKET APPLICATIONS
PROSPECTIVE APPLICATION OF SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)

Chapter- 7: PATENT ANALYSIS

PATENTS BY YEAR
PATENTS BY SIGNAL TRANSDUCTION THERAPIES CATEGORY (JAK AND PI3K)
PATENTS BY SIGNAL TRANSDUCTION THERAPIES TYPE
PATENTS BY COUNTRY
PATENTS BY COMPANY
PATENTS BY ASSIGNEE

Chapter- 8: CURRENT SITUATION

NEW TECHNOLOGIES AND PLATFORMS IN SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)
FACTORS AFFECTING THE SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET
CURRENT DRIVERS OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET
COLLABORATIONS/ACQUISITIONS

Chapter- 9: COMPANY PROFILES

ABBVIE INC.
AETERNA ZENTARIS INC.
AMGEN INC
ASTELLAS PHARMA INC.
ASTEX PHARMACEUTICALS INC
ASTRAZENECA PLC
BAYER HEALTHCARE PHARMACEUTICALS
CELL THERAPEUTICS INC
CURIS INC.
DAIICHI SANKYO CO. LTD
ELI LILLY AND CO.
EXELIXIS INC.
GALAPAGOS NV
GENENTECH INC
GILEAD SCIENCES INC.
GLAXOSMITHKLINE
INCYTE CORP.
INFINITY PHARMACEUTICALS INC.
ITALFARMACO S.P.A.
JANSSEN BIOTECH INC.
MEI PHARMA INC.
MERCK and CO. INC.
MILLENNIUM
NATIONAL CANCER INSTITUTE
NIPPON ZENYAKU KOGYO CO., LTD.
NOVARTIS INTERNATIONAL AG
NS PHARMA, INC
ONCOTHYREON INC
PATHWAY THERAPEUTICS LTD
PFIZER
PIRAMAL ENTERPRISES LIMITED
PORTOLA PHARMACEUTICALS INC
RIGEL PHARMACEUTICALS INC.
SANOFI ONCOLOGY
TEVA PHARMACEUTICALS INDUSTRIES LTD
TG THERAPEUTICS INC.
VERASTEM INC.
VERTEX PHARMACEUTICALS INC
WILEX AG
XCOVERY HOLDING COMPANY, LLC

Chapter- 10: APPENDIX I-ABBREVIATIONS

List of Tables

GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018
Table 1 : CLASSIFICATION OF JANUS KINASE (JAK)
Table 2 : CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K)
Table 3 : SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS
Table 4 : NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT
Table 5 : NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS
Table 6 : NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY
Table 7 : GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018
Table 8 : GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018
Table 9 : GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018
Table 10 : MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013
Table 11 : REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018
Table 12 : MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013
Table 13 : LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS
Table 14 : MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013
Table 15 : APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES
Table 16 : GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018
Table 17 : MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013
Table 18 : TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
Table 19 : NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
Table 20 : PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 21 : PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 22 : NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 23 : PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 24 : NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 25 : PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 26 : NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 27 : NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 28 : PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 29 : PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Table 30 : FUNDINGS IN SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)

List of Figures

GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018)
Figure 1 : STRUCTURE OF INC424 (RUXOLITINIB)
Figure 2 : STRUCTURE OF CP-690,550 (TOFACITINIB)
Figure 3 : STRUCTURE OF BARICITINIB (INC28050/LY3009104)
Figure 4 : STRUCTURE OF MOMELOTINIB (CYT-387)
Figure 5 : STRUCTURE OF AT9283
Figure 6 : STRUCTURE OF PACRITINIB (SB1518)
Figure 7 : STRUCTURE OF LY2784544
Figure 8 : STRUCTURE OF TG101348 (SAR302503)
Figure 9 : STRUCTURE OF BMS911543
Figure 10 : STRUCTURE OF LESTAURTINIB (CEP-701)
Figure 11 : STRUCTURE OF WP1066
Figure 12 : STRUCTURE OF AG490
Figure 13 : STRUCTURE OF AZD1480
Figure 14 : STRUCTURE OF WORTMANNIN
Figure 15 : STRUCTURE OF PERIFOSINE (KRX-0401)
Figure 16 : STRUCTURE OF LY294002
Figure 17 : STRUCTURE OF IDELALISIB (GS-1101, CAL-101)
Figure 18 : STRUCTURE OF PX-866
Figure 19 : STRUCTURE OF IPI-145
Figure 20 : STRUCTURE OF BKM120
Figure 21 : STRUCTURE OF COPANLISIB (BAY 80-6946)
Figure 22 : STRUCTURE OF PF-05212384 (PKI-587)
Figure 23 : STRUCTURE OF PICTILISIB (GDC-0941)
Figure 24 : STRUCTURE OF DACTOLISIB (BEZ235)
Figure 25 : STRUCTURE OF APITOLISIB (GDC-0980)
Figure 26 : STRUCTURE OF ZSTK474
Figure 27 : STRUCTURE OF SAR245409 (XL765)
Figure 28 : STRUCTURE OF APITOLISIB SAR245408 (XL147)
Figure 29 : STRUCTURE OF APITOLISIB BYL719
Figure 30 : GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2011-2018
Figure 31 : GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, 2011-2018
Figure 32 : GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, 2011-2018
Figure 33 : MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013
Figure 34 : REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2011-2018
Figure 35 : MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS BY REGION, 2013
Figure 36 : MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013
Figure 37 : GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, 2011-2018
Figure 38 : MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013
Figure 39 : TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
Figure 40 : NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
Figure 41 : PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/BIOMARKERS, 2011-2013
Figure 42 : PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Figure 43 : NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Figure 44 : PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Figure 45 : NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Figure 46 : PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Figure 47 : PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Figure 48 : PATENTS BY ASSGINEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.